Altimmune's Strategic Pivot from Obesity to Liver Disease May Finally Face Its First Test

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Altimmune typically reports earnings before market open, meaning Day 0 captures the first full trading session where investors react to results, and Day +1 reflects follow-through or reversal.

Altimmune's post-earnings price action has been highly volatile and directionally mixed, with an average absolute Day 0 move of 9.47% and an average Day 0 range of 13.71%. The most dramatic reaction came in November 2024, when the stock surged 29% on Day 0 following a strong earnings beat, though it gave back nearly all of that gain by Day +1.

More recently, the stock's reactions have been more muted. The August 2026 report saw a modest 2.3% decline on Day 0, while the May 2026 and March 2026 reports produced Day 0 moves of just 2% and 18%, respectively. The March 2026 session stands out as an outlier, with a sharp 18% drop on Day 0 that was partially reversed the following day.

Day +1 follow-through has been relatively subdued, averaging just 2.32% in absolute terms, suggesting that initial reactions tend to stabilize quickly. Investors should expect a Day 0 move in the high single digits to low double digits, with the potential for a larger swing if the company provides unexpected guidance on cash burn, trial timelines, or partnership discussions.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 10.95% by the November 13 expiration, which sits slightly above the stock's average historical Day 0 move of 9.47% but well below the average Day 0 range of 13.71%. This suggests the market is anticipating a moderately volatile reaction, though not as extreme as some of the larger historical swings.

Part 3: What Analysts Are Saying

Altimmune enjoys strong analyst support, with a consensus rating that translates to Strong Buy territory. Of the 12 analysts covering the stock, 9 rate it a Strong Buy, 3 rate it a Hold, and none recommend selling. The average recommendation score of 4.50 out of 5.0 reflects broad confidence in the company's clinical pipeline and commercial potential.

The average price target of $14.42 implies 647% upside from the current price of $1.93, with a wide range of outcomes: the high estimate of $28.00 suggests more than 1,300% upside, while the low target of $2.10 is only modestly above current levels. This dispersion reflects the binary nature of clinical-stage biotech investing—pemvidutide's success or failure in late-stage trials will determine whether the stock approaches the high end of the range or languishes near the low end.

Sentiment has remained unchanged over the past month, with the same 9-0-3 buy-hold-sell split. However, several analysts have adjusted their price targets in recent months. Evercore ISI lowered its target to $17 from $18, while Citizens cut its target to $11 from $14, reflecting tempered peak sales expectations and increased competitive pressure in the MASH and obesity markets. Despite these reductions, the consensus view remains decidedly bullish, supported by positive Phase 2 data in AUD and the successful initiation of the PERFORMA Phase 3 trial in MASH.

Part 4: Technical Picture

Altimmune is entering earnings in a deeply oversold technical position, with the Barchart Technical Opinion registering a 100% Sell signal—a reading that has intensified from 72% Sell a month ago and 100% Sell a week ago. The stock is trading at $1.93, below all key moving averages: the 5-day ($2.01), 10-day ($2.04), 20-day ($2.11), 50-day ($2.65), 100-day ($2.82), and 200-day ($3.16). This alignment of moving averages in descending order confirms a sustained downtrend across all timeframes.

Timeframe Analysis:

• Short-term (100% Sell): The near-term technical picture is uniformly negative, with the stock trading below even its shortest-term moving averages and showing no signs of stabilization.
• Medium-term (100% Sell): The intermediate trend remains firmly bearish, with the stock failing to hold support at the 50-day and 100-day moving averages.
• Long-term (100% Sell): The longer-term trend is equally weak, with the stock now 39% below its 200-day moving average and showing no technical support until the $1.90 level.

Trend Characteristics: The signal strength is classified as Strong with direction described as Strongest, indicating that the bearish momentum is both intense and accelerating heading into the earnings release.

The stock is trading near its 52-week low of $1.90 and has declined more than 70% from its 52-week high of $6.44, reflecting a combination of biotech sector weakness, dilution concerns following the April equity raise, and investor caution about the long timeline to PERFORMA readout in 2029. The technical setup is decidedly cautionary for earnings, with no nearby support levels and all momentum indicators pointing lower. A strong earnings beat or positive clinical update would need to be substantial to reverse the entrenched downtrend, while any disappointment on cash burn, trial enrollment, or partnership discussions could push the stock to new lows.